德谷胰岛素

参考资料仅供科学研究，不可用于个人用途。

货号：BCP23700CAS号：844439-96-9纯度：98%

在线咨询

购买咨询

全国免运费！免费咨询：400-099-8200 或手机联系：13472751340

* 必填项

请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。

Product name			* Applicant name
Catalog Number			* Institution/Company
* Email address			Phone number
Country			* Quantity Required
Remarks

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name			* Applicant name
Catalog Number			* Institution/Company
* Email address			Phone number
Country			* Quantity Required
Remarks

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name			* Applicant name
Catalog Number			* Institution/Company
* Email address			Phone number
Country			* Quantity Required
Remarks

基本信息与产品描述

CAS号	844439-96-9	货号	BCP23700
中文名	德谷胰岛素
英文名	Insulin degludec
中文别名
英文别名	Tresiba;
SMILES	CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C
化学名称
分子式	C274H411N65O81S6	分子量	6103.97
纯度	98%	配送	惯例下常温包邮
产品描述	Insulin Degludec is an ultra-long-acting insulin analogue used for glycemic control in Diabetes Mellitus. Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake and by preventing hepatic glucose production. Compared to endogenous insulin, this product has an added hexadecanedioic acid to lysine at the B29 position which allows for the formation of multi-hexamers. When injected subcutaneously, these multi-hexamers form a drug depot store from which monomers are slowly and continuously absorbed into the circulation. As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation. Compared to available long-acting analogues such as insulin glargine and insulin detemir, which have a duration of action of 20-24 hours, insulin degludec provides a consistent level of basal insulin over 42 hours with a low peak:trough ratio. Limitations of shorter acting analogues include more frequent dosing and less stable pharmacokinetics, which may negatively impact patient adherence and glucose control, particularly nocturnal control. Insulin Degludec was approved by the FDA in September 2015 as the product Tresiba, for use in providing glycemic control to adults with diabetes mellitus.

技术资料和支持

德谷胰岛素

关于瀚香生物科技

客服支持

订单

联系瀚香生物科技